Market Cap 4.72B
Revenue (ttm) 0.00
Net Income (ttm) -182.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 733,600
Avg Vol 784,462
Day's Range N/A - N/A
Shares Out 68.32M
Stochastic %K 96%
Beta 1.41
Analysts Strong Sell
Price Target $96.55

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 394 5230
Address:
Building 17, Suite 102b 221 Crescent Street, Waltham, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:52 PM
Actionable Trade Alert for $APGE: Market Context: $APGE is currently trading at $75.5, nearing its 60D high of $77.0. The RSI at 76.25 indicates that the stock is overbought, suggesting a potential pullback. However, the strong momentum reflected in the RSI and the proximity to the recent high could lead to a short-term bullish trend. Directional Bias: While the RSI suggests overbought conditions, the stock's position above both the 30-day MA (62.14) and 50-day MA (56.16) indicates a strong bullish trend. The recent high-low range shows significant volatility, which can be leveraged for potential gains. Trade Plan: - Suggested Entry: $75.5 - Stop Loss: $71.5 (5.3% below entry) - Take Profit Targets: 1. $78.0 (3.3% gain) 2. $80.0 (5.8% gain) 3. $88.5 (17.2% gain) With a potential ROI of over 17% at target 3, this trade offers a solid risk-reward ratio. Monitor RSI for signs of reversal. https://privateprofiteers.com
0 · Reply
Pika_Capital
Pika_Capital Dec. 4 at 1:44 AM
$ORKA $APGE $SYRE All 3 doubled pretty much. What a year for Pika. Ordered RTX 5090 as a Christmas gift 😂 time for upgrade baby.
0 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:09 PM
$APGE +4.32 - knocking on door # 52wk$ @Doozio
0 · Reply
Social_Idiot
Social_Idiot Nov. 25 at 1:05 AM
$APGE Model showing: Measuring gap with sell signal. Low risk.
0 · Reply
Gemola
Gemola Nov. 14 at 4:46 PM
$APGE Double doji sandwich. boolish
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 3:56 PM
breakout buzz $CDTX $RVMD $APGE $OWLT $CELC all tapping fresh 52-week highs. biotech acting like it found an extra gear today. what’s driving the surge? full breakdown inside. https://stocksrunner.com/news/2025-11-14-52-week-high-breakout-stocks-to-watch-right-now
0 · Reply
miller1m
miller1m Nov. 11 at 7:23 PM
$APGE absolutely a takeout candidate for big pharma. My prediction $180 plus eventually might happen, could be a bidding war here
0 · Reply
Pika_Capital
Pika_Capital Nov. 11 at 4:24 PM
$APGE what a run boyz. Oh wait, there is barely anyone here 😂
1 · Reply
d_risk
d_risk Nov. 10 at 4:28 PM
$APGE - Apogee Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors APGE’s latest 10-Q risk factors expand disclosures on third-party reliance, regulatory and patent risks, cybersecurity, global operations, financial institution exposure, and macroeconomic/geopolitical threats, while adding new risks on misconduct, tax, acquisitions, and product liability; litigation and analyst coverage risks removed. #Biotechnology #MacroeconomicRisk #GlobalOperations #Cybersecurity #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-Q/2025-11-10
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 1:34 PM
$APGE (+2.4% pre) Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 https://ooc.bz/l/83839
0 · Reply
Latest News on APGE
Apogee Therapeutics to Participate in Upcoming Conferences

Nov 3, 2025, 7:30 AM EST - 4 weeks ago

Apogee Therapeutics to Participate in Upcoming Conferences


Why Apogee Therapeutics Stock Triumphed on Thursday

Oct 9, 2025, 5:26 PM EDT - 2 months ago

Why Apogee Therapeutics Stock Triumphed on Thursday


Apogee Therapeutics: Engineering Biologic Dominance

Apr 14, 2025, 8:04 AM EDT - 8 months ago

Apogee Therapeutics: Engineering Biologic Dominance


Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 29, 2024, 1:00 PM EST - 1 year ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:52 PM
Actionable Trade Alert for $APGE: Market Context: $APGE is currently trading at $75.5, nearing its 60D high of $77.0. The RSI at 76.25 indicates that the stock is overbought, suggesting a potential pullback. However, the strong momentum reflected in the RSI and the proximity to the recent high could lead to a short-term bullish trend. Directional Bias: While the RSI suggests overbought conditions, the stock's position above both the 30-day MA (62.14) and 50-day MA (56.16) indicates a strong bullish trend. The recent high-low range shows significant volatility, which can be leveraged for potential gains. Trade Plan: - Suggested Entry: $75.5 - Stop Loss: $71.5 (5.3% below entry) - Take Profit Targets: 1. $78.0 (3.3% gain) 2. $80.0 (5.8% gain) 3. $88.5 (17.2% gain) With a potential ROI of over 17% at target 3, this trade offers a solid risk-reward ratio. Monitor RSI for signs of reversal. https://privateprofiteers.com
0 · Reply
Pika_Capital
Pika_Capital Dec. 4 at 1:44 AM
$ORKA $APGE $SYRE All 3 doubled pretty much. What a year for Pika. Ordered RTX 5090 as a Christmas gift 😂 time for upgrade baby.
0 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:09 PM
$APGE +4.32 - knocking on door # 52wk$ @Doozio
0 · Reply
Social_Idiot
Social_Idiot Nov. 25 at 1:05 AM
$APGE Model showing: Measuring gap with sell signal. Low risk.
0 · Reply
Gemola
Gemola Nov. 14 at 4:46 PM
$APGE Double doji sandwich. boolish
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 3:56 PM
breakout buzz $CDTX $RVMD $APGE $OWLT $CELC all tapping fresh 52-week highs. biotech acting like it found an extra gear today. what’s driving the surge? full breakdown inside. https://stocksrunner.com/news/2025-11-14-52-week-high-breakout-stocks-to-watch-right-now
0 · Reply
miller1m
miller1m Nov. 11 at 7:23 PM
$APGE absolutely a takeout candidate for big pharma. My prediction $180 plus eventually might happen, could be a bidding war here
0 · Reply
Pika_Capital
Pika_Capital Nov. 11 at 4:24 PM
$APGE what a run boyz. Oh wait, there is barely anyone here 😂
1 · Reply
d_risk
d_risk Nov. 10 at 4:28 PM
$APGE - Apogee Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors APGE’s latest 10-Q risk factors expand disclosures on third-party reliance, regulatory and patent risks, cybersecurity, global operations, financial institution exposure, and macroeconomic/geopolitical threats, while adding new risks on misconduct, tax, acquisitions, and product liability; litigation and analyst coverage risks removed. #Biotechnology #MacroeconomicRisk #GlobalOperations #Cybersecurity #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-Q/2025-11-10
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 1:34 PM
$APGE (+2.4% pre) Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 https://ooc.bz/l/83839
0 · Reply
Quantumup
Quantumup Nov. 10 at 11:41 AM
Oppenheimer reiterated $NKTR Outperform/$98 $APGE $CRVS $REGN $SNY LLY ABBV Here's what Oppenheimer said in its note to investors: Following the 3Q update on Thursday, NKTR presented additional findings from the REZOLVE-AD Ph2b study of rezpeg in atopic dermatitis in a late-breaking oral presentation at ACAAI. New results showed that, across dose cohorts, rezpeg treatment demonstrated significant and clinically meaningful improvements in prespecified ACQ-5 scores in AD patients who reported a history of asthma. We view the new findings as further strengthening rezpeg's differentiated profile for AD treatment, as we await results from the maintenance part of the study in 1Q26. Near term, we anticipate topline results from the Ph2 REZOLVE-AA study in alopecia areata in Dec., which could unlock additional upside potential given an arguably low bar for biologics in this untapped indication. We update our model and maintain Outperform.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 11:56 AM
$APGE Current Stock Price: $54.36 Contracts to trade: $55 APGE Nov 21 2025 Call Entry: $3.69 Exit: $7.32 ROI: 98% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 5:45 PM
Craig-Hallum updates rating for Apogee Therapeutics ( $APGE ) to Buy, target set at 109.
0 · Reply
IN0V8
IN0V8 Nov. 3 at 2:53 PM
$APGE bUY RBC raises target price to $70 from $60
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 2:38 PM
RBC Capital has updated their rating for Apogee Therapeutics ( $APGE ) to Outperform with a price target of 70.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:24 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:43 PM
Mizuho has adjusted their stance on Apogee Therapeutics ( $APGE ), setting the rating to Outperform with a target price of 105.
0 · Reply
Rvazstocksfl
Rvazstocksfl Oct. 21 at 12:27 PM
$APGE wow 🤩
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
1 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 1:21 AM
$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting
0 · Reply
Pika_Capital
Pika_Capital Oct. 11 at 12:02 PM
$PTGX proceeds will be redeployed into $IMVT, $APGE (possibly more $GMAB ) and across bunch of other names in pfolio. May reenter $BHVN again but not sure, it's a lower conviction name going into PDUFa.
2 · Reply
swampwiz0
swampwiz0 Oct. 10 at 12:25 AM
$APGE CHA-CHING AGAIN!
0 · Reply